Tacrolimus Capsule, Coated, Extended Release
Product Images NDC 71432-2001

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tacrolimus (NDC 71432-2001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chengdu Suncadia Medicine Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Tacrolimus 01)

Chemical structure of tacrolimus, the active ingredient in tacrolimus extended-release capsules. The diagram shows the molecular framework with various functional groups and atoms labeled.*

FDA Label Image

Figure 1 (Tacrolimus 02)

A chart showing the pharmacokinetic interactions of tacrolimus extended-release (ER) capsules when co-administered with ketoconazole or rifampin. It plots the geometric mean ratio of test to reference with 90% confidence intervals for Cmax and AUC values, comparing tacrolimus ER with co-administered drugs versus tacrolimus alone given as a single dose.*

FDA Label Image

Figure 2 (Tacrolimus 03)

A pharmacokinetic graph displaying the geometric mean ratio and 90% confidence intervals of tacrolimus Cmax and AUC when co-administered with various drugs (telaprevir, boceprevir, magnesium-aluminum hydroxide, voriconazole, posaconazole) compared to tacrolimus immediate release alone. The horizontal axis is logarithmic, ranging from 0.1 to 100, indicating changes in tacrolimus exposure.*

FDA Label Image

0.5 (Tacrolimus 04)

Packaging label for Tacrolimus Extended-Release Capsules 0.5 mg, oral coated capsules. The label states a 50-capsule package with blister cards containing 10 capsules each. Manufactured by Chengdu Suncadia Medicine Co., Ltd., distributed by eVenus Pharmaceutical Laboratories, Inc. The packaging includes dosing instructions, note on capsule fill, storage conditions, and a warning that the package is not child-resistant.*

FDA Label Image

1 (Tacrolimus 05)

Tacrolimus Extended-Release Capsules 1 mg per Capsule oral dosage packaging label. The label indicates 50 capsules (5 blister cards of 10 capsules each) with a storage recommendation of 25°C and a warning that the unit-dose package is not child-resistant. Manufactured by Chengdu Suncadia Medicine Co., Ltd, distributed by eVenus Pharmaceutical Laboratories, Inc. The label includes active and inactive ingredients, dosage instructions, and the NDC code 71432-2002-1.*

FDA Label Image

5 (Tacrolimus 06)

Packaging label for Tacrolimus Extended-Release Capsules, 5 mg per capsule, oral dosage form. The label indicates a 50-capsule unit-dose package, consisting of 5 blister cards with 10 capsules each. It includes manufacturer information (Chengdu Suncadia Medicine Co., Ltd.) and distributor details (eVenus Pharmaceutical Laboratories, Inc.). The label notes the capsules are not child-resistant and instructs dispensing the enclosed medication guide. The design features black text on a white background with orange highlights for strength.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.